

**Amendments to the Claims:**

Please amend the claims as follows:

1-58. (Cancelled)

59. (Previously Presented) An isolated Neisserial bleb preparation from a Neisserial strain with an L3 LOS immunotype wherein the *lgtB* gene has been inactivated resulting in an intermediate LOS structure in which the terminal galactose residue and sialic acid are absent.

60. (Previously Presented) The Neisserial bleb preparation of claim 59, wherein the Neisserial strain is a Neisserial meningococcal strain of serogroup B.

61. (New) The Neisserial bleb preparation of claim 59, wherein the Neisserial strain cannot synthesize capsular polysaccharide.

62. (New) An immunogenic composition comprising the Neisserial bleb preparation of claim 59, and a pharmaceutically acceptable excipient.

63. (New) The immunogenic composition of claim 62, comprising an adjuvant.

64. (New) The immunogenic composition of claim 62, further comprising a capsular polysaccharide or oligosaccharide, wherein the polysaccharide or oligosaccharide is from a bacterium selected from the group consisting of meningococcus serogroup A, meningococcus serogroup C, meningococcus serogroup W-135, meningococcus serogroup Y, and *H. influenzae* type b.